Advertisement

Radiological Terrorism

Chapter
  • 746 Downloads

Radiological terrorism is the use of radioactive material to cause human casualties, environmental destruction and maximum disruption, panic and fear (1) in the general population for political purposes. Since the atomic bombing of Hiroshima in 1945, with 150,000 casualties and 75,000 fatalities (2), people have feared nuclear explosives more than any other weapons of mass destruction, because of the ability of these weapons to cause immediate devastation and trauma, and because radiation, undetected by human senses, can cause ongoing morbidity and mortality, including cancer, years after exposure (3).

Keywords

Prussian Blue Radioactive Material Potassium Iodide Radiation Injury Lifetime Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Leikin, JB, McFee, RB, Walter, FG, Edsall, K. A Primer for Nuclear Terrorism. Disease-a-Month, 49(8):485–516, 2003.PubMedCrossRefGoogle Scholar
  2. 2.
    Waselenko, JK, MacVittie, TJ, Blakely, WF, et al. Medical Management of the ARS: Recommendations of the Strategic National Stockpile Radiation Working Group. Annals of Internal Medicine, 140(12):1037–1051, 2004.PubMedGoogle Scholar
  3. 3.
    Federation of American Scientists. Special Weapons Primer. Weapons of Mass Destruction. http://www.fas.org/nuke/intro/nuke/intro.htm, last accessed 9–04–05.
  4. 4.
    Hogan, DE, Kellison, T. Nuclear Terrorism. The American Journal of the Medical Sciences, 323(6):341–349, 2002.PubMedCrossRefGoogle Scholar
  5. 5.
    Koenig, KL, Goans, RE, Hatchett, RJ, et al. Medical Treatment of Radiological Casualties: Current Concepts. Annals of Emergency Medicine, 45(6):643–652, 2005.PubMedCrossRefGoogle Scholar
  6. 6.
    Ring, JP. Radiation Risks and Dirty Bombs. Health Physics 86(2 Suppl.):S42–S47, 2004.PubMedCrossRefGoogle Scholar
  7. 7.
    Military Medical Operations Armed Forces Radiobiology Research Institute. Medical Management of Radiological Casualties Handbook. Second Edition. Bethesda, Maryland 20889–5603 http://www.afrri.usuhs.mil April 2003.
  8. 8.
    Centers for Disease Control and Prevention. ARS: A Fact Sheet for Physicians, http://www.bt.cdc.gov/radiation/pdf/arsphysicianfactsheet.pdf, last accessed 9–11–05.
  9. 9.
    Oak Ridge Associated Universities, Oak Ridge Institute for Science and Education. Guidance for Radiation Accident Management, Managing Radiation Emergencies, Guidance for Hospital Medical Management. Radiation Emergency Assistance Center Center/Training Site (REAC/TS), http://www.orau.gov/reacts, last accessed 1–01–06.
  10. 10.
    Walker, RI, Cerveny, RJ (Eds.). Textbook of Military Medicine Medical Consequences of Nuclear Warfare. Falls Church, VA: Office of the Surgeon General, 1989. Available at http://www.afrri.usuhs.mil.
  11. 11.
    Goans, RE, Holloweay, EC, Berger, ME, Ricks, RCF. Early Dose Assessment in Criticality Accidents. Health Physics, 81(4):446–449, 2001.PubMedCrossRefGoogle Scholar
  12. 12.
    Military Medical Operations Armed Forces Radiobiology Research Institute. Biodosimetry Assessment Tool (BAT) Software Application. http://www.afrri.usuhs.mil/www/outreach/biodostools.htm#BATregister, last accessed 12/31/05.
  13. 13.
    Centers for Disease Control and Prevention. Prenatal Radiation Exposure: A Fact Sheet for Physicians, March 23, 2005. http://www.bt.cdc.gov/radiation/pdf/prenatalphysician.pdf, last accessed 1–29–06.
  14. 14.
    National Council on Radiation Protection and Measurements. NCRP Report No. 128: Radionuclide Exposure of the Embryo/Fetus. Bethesda, Maryland: NCRP, 1998, http://www.ncrponline.org/ncrprpts.html (last accessed 1–29–06).
  15. 15.
    United States Food and Drug Administration, Center for Drug Evaluation and Research. Guidance: Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies, http://www.fda.gov/cder/guidance/4825fnl.pdf, last accessed 1–01–06.
  16. 16.
    United States Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry on Prussian Blue for Treatment of Internal Contamination with Thallium or Radioactive Cesium, Availability. Federal Register/Vol. 68, No. 23/Tuesday, February 4, 2003/Notices, http://www.fda.gov/OHRMS/DOCKETS/98fr/03–2597.pdf, last accessed 1–01–06.
  17. 17.
    Hughes, WT, Armstrong, DN, Bodey, GP, et al. Guidelines for the use of Antimicrobial Agents in Neutropenic patients with Cancer. Clinical Infectious Diseases, 34:730–751, 2002.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Personalised recommendations